Medipress Health 2025: Cash Still Exceeds the Market Value, but Access to It Is Not Clean Yet

Getting to Know the Company

Medipress Health no longer reads like an R&D partnership trying to build a broader portfolio. By the end of 2025 it looked more like a tiny public wrapper with NIS 11.97 million of cash, an investment portfolio marked at NIS 6.2 million, almost all of it tied to P-Cure, and a current market value of only about NIS 8.1 million based on a unit price of NIS 0.542 and 15.012 million units outstanding. That is the right starting point: this is not just another medtech story, but a micro holding vehicle the market is already reading through a realization lens.

What is actually working today? At the partnership level there is no financing stress. Total loss narrowed to NIS 2.19 million from NIS 4.88 million in 2024, operating cash use fell to NIS 512 thousand, and most of the cash balance sits in deposits. What is still unresolved? 90.4% of the portfolio's fair value depends on P-Cure, Nervio was marked down sharply, and Gynamics and Spring are effectively out of the story.

The easy misread is to assume the discount comes only from biotech risk. That is incomplete. The numbers suggest the market is also discounting the cash cushion itself. Market value is below cash on hand, so the real question is not just portfolio quality, but whether and when that value can actually reach unit holders.

That is the active bottleneck. During 2024 management changed, and in August 2024 the audit committee and the general partner's board adopted an in-principle decision to pursue a Run Off plan of asset realization and cessation of activity. The thesis has therefore shifted from building a new portfolio to realizing what is left. The problem is that the company still has not converted that direction into a clear timetable, a distribution framework, or a step-by-step monetization map.

The economic map looks like this:

These numbers also explain the practical constraint. This is a very small listed participation unit with a last daily trading turnover of just NIS 15.9 thousand. So even if one accepts that there is a value gap, the path to a rerating is still messy: liquidity is thin, realization events are not yet defined, and the main holding is still not a hard liquidity event.

Events and Triggers

The quiet shift from growth story to realization story

The first trigger: in March 2024 directors appointed by controlling shareholders demanded discussion of ending the tenure of CEO and chairman Prof. Yosef Peres and of dissolving the partnership. New directors were appointed, Roy Levy replaced Peres as CEO, and later an in-principle Run Off plan was approved. This is a major structural change because it turns the central question from "what new assets will Medipress buy?" into "how much of the existing asset base can actually be realized for unit holders?"

The second trigger: at the start of 2025, 1.501 million non-traded options expired. They had an exercise price of NIS 2.6 per unit, far above the current unit price, so this is not a major economic event, but it does remove one old overhang.

P-Cure is still the only asset that can really move the needle

The third trigger: P-Cure is now the anchor asset. Around that holding, 2025 brought several concrete developments: an agreement with Hadassah to supply a system plus a ten-year service agreement subject to a clinical license, a new agreement for additional operating and planning systems for the SPHIC sales project in China, advanced installation progress at SPHIC, broader FDA approval for use across the whole body, ongoing support activity in China, and higher selling and marketing investment in the US.

What really matters is not the event list itself, but how those developments translated into value. The economic review kept Medipress's P-Cure holding unchanged in dollar terms at about $1.757 million, even after a year in which P-Cure reportedly delivered about NIS 5.3 million of operating profit in 2024, about NIS 5 million of positive cash flow in 2025, and roughly $3.8 million of cash at the review date. The holding's value in shekels therefore fell to NIS 5.605 million mainly because of the weaker dollar, not because of a lower dollar valuation.

That is an important cut. On one side, it reduces the risk of an overly aggressive mark. On the other side, it also means the core asset still has not produced an outside pricing event, such as a priced funding round or a realization, that would force a higher value in the accounts and in the market's reading.

Nervio moved from clean optionality to bridge asset

The fourth trigger: Nervio is no longer presented as a clean growth option. In the valuation review, Nervio was shown with roughly $760 thousand of cash and a monthly cash burn of roughly $145 thousand, which means only about five months of runway absent new funding. At the same time, management indicated talks with a strategic partner that could fund R&D, but those talks had not yet matured. Under those assumptions Medipress's Nervio holding was cut from NIS 1.099 million to NIS 595 thousand.

That is more than a numerical markdown. It means Nervio is now better understood as a bridge asset rather than as an open-ended technology option.

What has already dropped out of the thesis

The fifth trigger: Gynamics and Spring no longer drive the case. Gynamics is described as inactive and without active employees, while Spring is described as having ceased activity and being in a court-led closure process. Anyone still reading Medipress as a diversified basket of medical technology options is reading an old story. By the end of 2025 this was a highly concentrated portfolio with one meaningful asset, one smaller residual asset, and far less diversification than the partnership's name may suggest.

Efficiency, Profitability, and Competition

At the partnership level Medipress has no real operating business that generates recurring earnings. So profitability analysis needs to start with the question what actually moves the P&L: portfolio revaluation, G&A, and interest income on the cash balance.

The good news in 2025 is that erosion slowed. G&A fell to NIS 1.383 million from NIS 1.690 million, down 18.2%. Fair-value losses on investments fell to NIS 1.272 million from NIS 3.722 million, down 65.8%. Together they reduced total loss to NIS 2.189 million.

But this should not be confused with fresh value creation. This is not a breakout year. It is a year in which the rate of erosion moderated. Even finance income, which reached NIS 472 thousand, mainly reflects deposit carry rather than a new operating engine. In other words, part of the improvement came from the cash box still working, not from the portfolio stepping into a new phase.

The portfolio structure tells the uncomfortable part of the story. P-Cure accounts for 90.4% of the investment portfolio's fair value at year-end 2025, and Nervio for most of the remaining 9.6%. There is no diversification cushion here. Once Nervio was marked down, nearly the entire analytical frame was left hanging on P-Cure.

There is also an earnings-quality issue that matters. Partnership-level revenue was zero in 2025 versus NIS 134 thousand in 2024. So anyone looking only at the narrower loss may conclude the company is becoming a leaner, more stable business. In reality, this is a partnership whose better result came mainly from lower overhead and smaller revaluation damage, not from building an income stream that belongs to unit holders.

The competitive reading of the portfolio now comes mostly through P-Cure and Nervio. P-Cure is trying to reduce the cost barrier in proton therapy and broaden adoption. Nervio is built around an AI-based solution for the IONM market, where shortages of expert neurophysiologists are part of the problem its product is trying to solve. But for Medipress unit holders this is now second-order. The first-order issue is no longer whether those portfolio companies are interesting, but whether they can produce a price event and a liquidity event.

Cash Flow, Debt, and Capital Structure

This is the core section because Medipress now looks far more like a cash box with a thin portfolio layer than like a growing investment platform.

The right bridge here is all-in cash flexibility

On an all-in cash flexibility basis, the partnership ended 2025 with NIS 11.967 million of cash and cash equivalents after only NIS 512 thousand of net operating cash use, with no new portfolio investment outflow during the year and no financial debt to service. Of that balance, NIS 11.709 million sat in a short-term deposit yielding 4%, and another NIS 258 thousand sat in current accounts.

That means the immediate risk at the partnership level is not classic liquidity risk. There is no debt wall, no covenant pressure, and no obvious need to raise capital at the Medipress level. Current liabilities are only NIS 346 thousand. In that sense the balance-sheet picture is much stronger than the market price implies.

But this is also exactly where the gap between accounting cash and accessible value begins. The partnership agreement sets semiannual management fees of 0.4% of total assets, including cash, and also a 20% promote on net realization proceeds subject to threshold conditions. The general partner waived management fees in 2022 through 2024, and part of 2025 was also waived, but the contractual framework itself remains in place. So anyone looking at NIS 12 million of cash as if it were NIS 12 million ready for distribution is missing the fact that time, structure, and overhead still matter.

That also helps explain why market value sits below not only book equity of NIS 17.898 million, but even below cash alone. The market is not necessarily saying the cash does not exist. It is saying that cash is not yet viewed as clean, near-term, low-friction value.

There is also a subtle but important contradiction inside the same filing. On the one hand, August 2024 brought an in-principle Run Off decision aimed at realizing assets and ending activity. On the other hand, the cash note still describes the cash and deposits as mainly intended for existing and additional target-company investments and for funding operations over the next 12 months. That is the heart of the case. The strategic direction has changed, but the realization mechanism has not yet been translated into a hard execution language.

Outlook

First finding: 2025 did not create new balance-sheet value. It mainly slowed the pace of erosion.

Second finding: P-Cure progressed operationally, but that still did not turn into an outside event that would lift the holding's dollar value or create liquidity for Medipress.

Third finding: Nervio is already being read as a bridge situation, not as a clean growth asset.

Fourth finding: the market is now discounting not just the portfolio, but also the uncertainty around the Run Off path, the cost of time, and thin liquidity.

Fifth finding: the next test is not partnership-level financing. It is whether management can turn the asset cushion into a credible realization path.

That makes 2026 look like a bridge year. Not a growth year, not a reset year, and certainly not a breakout year. It is a year in which Medipress needs to prove that it can turn cash and marked portfolio value into something the market can actually price with confidence.

The first thing that has to happen over the next 2 to 4 quarters is strategic clarity. If Run Off is the real direction, the market will need detail: priorities, timing, the relationship between preserving cash and making follow-on investments, and whether management truly intends to exhaust the current portfolio before anything else.

The second thing is a proof event at P-Cure. That could be a priced funding round, commercialization evidence that carries a price signal, or another hard marker showing that the agreements and approvals cited for 2025 are translating into revenue, orders, or some other monetizable base. As long as the dollar value of the holding remains flat, Medipress will stay stuck between "there is an asset here" and "there is an asset here that can actually be realized."

The third thing is a resolution at Nervio. If the strategic partner actually comes in and funds R&D, further erosion may stop. If not, even the small residual value could continue to shrink. At the Medipress level this is not the biggest line on the balance sheet, but it is still a useful signal for how the remaining portfolio is being handled.

The fourth thing is expense discipline at the partnership level. G&A of NIS 1.383 million is still meaningful for an entity with no operating business and no revenue. In 2025 deposit income helped offset some of the drag. If rates fall, or if costs rise again, the discount on cash is likely to remain.

Risks

The first risk is extreme concentration. P-Cure represents almost the entire investment portfolio. Even with a healthy cash balance, nearly all of the case for value above cash depends on one asset.

The second risk is the gap between accounting value and realizable value. The partnership measures its holdings at fair value through profit and loss, but what matters to unit holders is when an actual realization event appears. Without that, even a relatively conservative fair-value mark may not convince the market.

The third risk is time erosion. Even without financial debt, a small vehicle with management costs, salaries, advisers, and partnership mechanics can grind through cash year after year. Looking only at year-end cash misses the cost of waiting.

The fourth risk is a discount that simply stays a discount. With daily trading turnover of only tens of thousands of shekels and a very small market value, valuation gaps can remain open for a long time. That matters especially in a company whose story has already shifted from portfolio building to value realization.

The fifth risk is external funding dependence at the target-company level. At Gynamics the story is effectively over, Spring is already in closure, and at Nervio funding is still a live issue. Even at P-Cure, the attached economic review mentions another fundraise that is only at an early stage. So even if the partnership itself has no near-term financing pressure, part of the value it carries still depends on the ability of portfolio companies to raise capital or convert technical progress into commercialization.

Conclusion

Medipress ends 2025 with a balance sheet that is materially stronger than the market price suggests. That is what supports the thesis. What blocks a cleaner read is not existential risk at the partnership level, but the lack of a clear realization path, the high dependence on P-Cure, and the fact that even the cash cushion is still not viewed as fully clean or accessible. Over the short to medium term, market interpretation will be driven less by whether assets exist and more by whether there is a credible path to monetize them.

Current thesis in one line: Medipress now reads like a Run Off partnership with a meaningful cash cushion, but the market still refuses to give full credit to either the cash or P-Cure until a credible realization path appears.

What has changed versus the older understanding of the company? It is much less a broad option basket and much more a story about realization, value access, and cost discipline.

The strongest counter-thesis is that the discount is deserved: cash will keep eroding, P-Cure will remain an illiquid asset without a hard price event, and Nervio shows how quickly theoretical value can weaken when funding is not secured.

What could change the market read? A clear Run Off roadmap, a real pricing event at P-Cure, and evidence that partnership-level costs can remain contained without eating into the cash cushion.

Why does this matter? Because this is no longer mainly a medtech dream test. It is a value-capture test: can a small listed partnership turn assets, time, and cash into accessible value for unit holders?

What has to happen over the next 2 to 4 quarters for the thesis to strengthen? Clarity on the realization plan, an external pricing signal at P-Cure, and stabilization at Nervio. What would weaken it? Continued delay on realization, renewed cost drift, or further erosion in the core asset base.